Last reviewed · How we verify
Placebo and celecoxib
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Placebo and celecoxib |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Celecoxib is a selective COX-2 inhibitor that preferentially blocks COX-2 over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract. This selectivity was designed to provide anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs. The placebo arm in this context serves as a control comparator in clinical trials.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Primary dysmenorrhea
- Familial adenomatous polyposis (FAP)
Common side effects
- Headache
- Dyspepsia
- Abdominal pain
- Diarrhea
- Nausea
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (PHASE1)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
- Timed Aspirin Chronobiome Study (EARLY_PHASE1)
- LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) (PHASE2)
- Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy (NA)
- Celecoxib for ENT Pain Management (PHASE2)
- A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PHASE2)
- Preoperative Gabapentin vs Placebo for Vaginal Prolapse Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: